Sovaldi 150 mg/1
SOFOSBUVIR · PELLET · Gilead Sciences, Inc.
No Recall History
Plain English
Sovaldi is a pellet containing sofosbuvir at 150 mg/1, taken oral. Manufactured by Gilead Sciences, Inc..
Key Facts
- Brand Name
- Sovaldi
- Generic Name
- SOFOSBUVIR
- NDC Code (Product)
61958-1504- Manufacturer
- Gilead Sciences, Inc.
- Strength
- 150 mg/1
- Dosage Form
- PELLET
- Route
- ORAL
- Marketing Status
- Application #
- NDA212480
- Drug Class
- Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]
- Marketing Start
- 08/28/2019
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
fatigue2,312 reports
drug ineffective1,930 reports
hepatitis c1,735 reports
headache1,643 reports
nausea1,393 reports
off label use1,385 reports
anaemia1,188 reports
insomnia1,062 reports
hepatocellular carcinoma911 reports
treatment failure836 reports
Frequently Asked Questions
What is Sovaldi used for?
Sovaldi contains SOFOSBUVIR. It is a pellet taken oral. Consult your doctor for specific uses.
Is Sovaldi a controlled substance?
Sovaldi is not classified as a controlled substance by the DEA.
What is the generic name for Sovaldi?
The generic name for Sovaldi is SOFOSBUVIR. There are 1 other brand versions of SOFOSBUVIR.
What is the NDC code for Sovaldi 150 mg/1?
The NDC (National Drug Code) for Sovaldi 150 mg/1 is 61958-1504, listed by Gilead Sciences, Inc..